The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 14: 1922 - 1927

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.14.004

Basic Research

The role of NLRP3 signaling pathway in allergic rhinoconjunctivitis

  • Yubo GONG ,
  • Xiaohua GUO ,
  • Wenjun LU ,
  • Yuanchao LI ,
  • Changyu QIU ,
  • Yuanyuan SHI ,
  • Liping XIA ,
  • Lin SHI ,
  • Wei WU ,
  • Ling. LUO
Expand
  • *.Department of Ophthalmology，Strategic Support Force Medical Center，Beijing 100101，China

Received date: 2023-05-17

  Online published: 2024-07-15

Fold

Abstract

Objective The objective of this study was to establish a mouse model of allergic rhinoconjunctivitis and investigate the role of the NLRP3 signaling pathway in allergic rhinoconjunctivitis. Methods Thirty-three female C57 mice （SPF） were randomLy divided into 3 groups： the control group， the experimental group， and the NLRP3-/- group. On days 0， 4， 7， 14， and 21， the experimental group and NLRP3-/- group received a 0.2 mL intraperitoneal injection of medicine containing OVA （100 μg） and adjuvant Al（OH）3 （4 mg）， respectively. After an interval of 3 days， each eye and nose were dosed with 10 μL of 5% OVA for five consecutive days a week to induce allergic symptoms. During sensitization and excitation stages， the control group was replaced with an equivalent amount of PBS. Ocular and nasal symptoms were observed and scored. The levels of OVA-specific IgE， IL-4， IL-17， and IL-18 in serum were measured using ELISA， while changes in palpebral conjunctiva and nasal mucosa were assessed by hematoxylin-eosin staining. The expression of NLRP3 mRNA in conjunctival tissue and nasal mucosa was determined using real-time PCR analysis. Statistical analysis was performed using SPSS17.0 software with P < 0.05 considered as statistically significant difference. Results The experimental group and NLRP3-/- group exhibited induced nasal and ocular allergic symptoms. In the experimental group， the duration of nasal allergy symptoms was （10.500 ± 1.080） days， while the duration of eye allergy symptoms was （20.300 ± 2.058） days. In the NLRP3-/- group， the duration of nasal allergy symptoms was （13.400 ± 1.955） days， and for eye allergy symptoms it was （20.900 ± 2.132） days. The duration of nasal allergies in the NLRP3-/- group significantly exceeded that in the experimental group （P < 0.05）， whereas there were no significant differences observed in eye allergy durations between these two groups （P > 0.05）. Levels of OVA-specific IgE， IL-4， and IL-17 were significantly higher in both the experimental and NLRP3-/- groups compared to those in the control group （P < 0.05）. Additionally， serum IL-18 content increased significantly in the experimental group when compared with both control and NLRP3-/- groups （P < 0.05）. Conjunctival tissue lesions as well as nasal mucosa damage were evident in both experimental and NLRP3-/- groups. mRNA expression levels of NLRP3 within conjunctival tissue and nasal mucosa from the experimental group showed a significant increase when compared to those from both control and NLRP3-/- groups（P < 0.05）. Conclusion Allergic rhinoconjunctivitis pathogenesis is influenced by various factors； however， the involvement of NLPR3 signaling pathway promotes its development.

Key words： allergic rhinoconjunctivitis; ovalbumin; IgE; NLRP3

Cite this article

Yubo GONG , Xiaohua GUO , Wenjun LU , Yuanchao LI , Changyu QIU , Yuanyuan SHI , Liping XIA , Lin SHI , Wei WU , Ling. LUO . The role of NLRP3 signaling pathway in allergic rhinoconjunctivitis[J]. The Journal of Practical Medicine, 2024 , 40(14) : 1922 -1927 . DOI: 10.3969/j.issn.1006-5725.2024.14.004

References

1 BILANCIA M， PASCULLI G， DI BONA D. A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy［J］. PLoS One， 2020，15（5）：e0232753. doi:10.1371/journal.pone.0232753
2 RATHINAM V A， FITZGERALD K A. Inflammasome Complexes： Emerging Mechanisms and Effector Functions［J］. Cell， 2016，165（4）：792-800. doi:10.1016/j.cell.2016.03.046
3 宫玉波，石圆圆，李元超，等. 变应性鼻结膜炎模型小鼠的建立［J］. 中国组织工程研究， 2022，26（32）：5143-5147. doi:10.12307/2022.890
4 CIPRANDI G， LEONARDI S， ZICARI A M， et al. Allergic rhinoconjunctivitis： pathophysiological mechanism and new therapeutic approach［J］. Acta Biomed， 2020，91（1）：93-96.
5 邹昊宇，胡鸿运，刘嫡，等. 千里光通过NLRP3/Caspase-1/IL-1β通路对过敏性结膜炎大鼠角结膜炎症的影响［J］. 中药新药与临床药理， 2019，30（11）：1346-1351.
6 XIAO Y， XU W， SU W. NLRP3 inflammasome： A likely target for the treatment of allergic diseases［J］. Clin Exp Allergy， 2018，48（9）：1080-1091. doi:10.1111/cea.13190
7 万慧娟. NLRP3炎性小体及下游因子IL-1β/IL-18在变应性鼻炎大鼠模型中的表达及意义［D］. 郑州：郑州大学， 2015. doi:10.3760/cma.j.issn.1673-0860.2015.02.011
8 YANG Z， LIANG C， WANG T， et al. NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis［J］. Biochem Biophys Res Commun， 2020，522（1）：61-67. doi:10.1016/j.bbrc.2019.11.031
9 LESZCZY?SKA K， JAKUBCZYK D， GóRSKA S. The NLRP3 inflammasome as a new target in respiratory disorders treatment［J］. Front Immunol， 2022，13：1006654. doi:10.3389/fimmu.2022.1006654
10 潘徐彪，李向玉，王志鑫，等. NLRP3-（Caspase-1）/IL-1β信号通路的研究进展［J］. 中国医药导报， 2019，16（1）：41-44.
11 KIM J K， JIN H S， SUH H W， et al. Negative regulators and their mechanisms in NLRP3 inflammasome activation and signaling［J］. Immunol Cell Biol， 2017，95（7）：584-592. doi:10.1038/icb.2017.23
12 黄静，卢建峰，马萍. 中医药干预NLRP3炎症小体治疗相关疾病的研究进展［J］. 中药与临床， 2018，9（5）：57-60.
13 蒋丹露，刘阳阳，孙如愚，等. NLRP3炎症小体介导的炎症相关疾病研究进展［J］. 生命科学， 2017，29（9）：898-907. doi:10.13376/j.cbls/2017120
14 OZAKI E， CAMPBELL M， DOYLE SL. Targeting the NLRP3 inflammasome in chronic inflammatory diseases： current perspectives［J］. J Inflamm Res， 2015，8：15-27. doi:10.2147/jir.s51250
15 陈永春，刘延刚，宗英，等. NLRP3炎症小体与相关系统疾病研究进展［J］. 北京医学， 2016，38（3）：263-265. doi:10.15932/j.0253-9713.2016.3.024
16 HERATH KHINM， CHO J， KIM H J， et al. Polyphenol containing Sargassum horneri attenuated Th2 differentiation in splenocytes of ovalbumin-sensitised mice： involvement of the transcription factors GATA3/STAT5/NLRP3 in Th2 polarization［J］. Pharm Biol， 2021，59（1）：1464-1472. doi:10.1080/13880209.2021.1992451
17 刘溪源，喻京生. 祛风明目丸对实验性自身免疫性葡萄膜炎大鼠NLRP3、ASC、IL-1β表达的影响［J］. 湖南中医药大学学报，2023，43（10）：1779-1785. doi:10.3969/j.issn.1674-070X.2023.10.005
18 BRANDLI A， VESSEY K A， FLETCHER E L. The contribution of pattern recognition receptor signalling in the development of age related macular degeneration： the role of toll-like-receptors and the NLRP3-inflammasome［J］. J Neuroinflammation， 2024，21（1）：64. doi:10.1186/s12974-024-03055-1
19 BAI X， LIU P， SHEN H， et al. Water-extracted Lonicera japonica polysaccharide attenuates allergic rhinitis by regulating NLRP3-IL-17 signaling axis［J］. Carbohydr Polym， 2022，297：120053. doi:10.1016/j.carbpol.2022.120053
20 BAI M T， LI Y， HU Z L. Ragweed pollen induces allergic conjunctivitis immune tolerance in mice via regulation of the NF-κB signal pathway［J］. Int J Ophthalmol， 2021，14（7）：955-964. doi:10.18240/ijo.2021.07.01
21 WEATHERLY L M， SHANE H L， FRIEND S A， et al. Topical Application of the Antimicrobial Agent Triclosan Induces NLRP3 Inflammasome Activation and Mitochondrial Dysfunction［J］. Toxicol Sci， 2020，176（1）：147-161. doi:10.1093/toxsci/kfaa056
22 ZHANG W， BA G， TANG R， et al. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model［J］. Int Immunopharmacol， 2020，83：106394. doi:10.1016/j.intimp.2020.106394
23 GUAN M， MA H， FAN X， et al. Dexamethasone alleviate allergic airway inflammation in mice by inhibiting the activation of NLRP3 inflammasome［J］. Int Immunopharmacol， 2020，78：106017. doi:10.1016/j.intimp.2019.106017
24 KELLEY N， JELTEMA D， DUAN Y， et al. The NLRP3 Inflammasome： An Overview of Mechanisms of Activation and Regulation［J］. Int J Mol Sci， 2019，20（13）：3328. doi:10.3390/ijms20133328
25 XU S， WANG D， TAN L， et al. The role of NLRP3 inflammasome in type 2 inflammation related diseases［J］. Autoimmunity， 2024，57（1）：2310269. doi:10.1080/08916934.2024.2310269
Options
Outlines

/

〈 〉